Document Type



Available under a Creative Commons Attribution Non-Commercial Share Alike 4.0 International Licence



Publication Details

Presented at Molecular Medicine Ireland Education & Training Annual Scientific Meeting 2014


• Alzheimer’s disease (AD) is the most common cause of dementia and affects nearly 40,000 individuals in Ireland. • The b-amyloid peptide (Ab) plays a key role in the pathogenesis of the AD and the presence of Ab plaques in the brain is diagnostic. •The hypothesis posits that Ab deposition is a critical factor in the disease process and that production and clearance of Ab are key drivers of the disease1. •Flux of Ab from the brain is believed to contribute to the overall level of Ab within in brain2 and antibody mediated brain-to-blood efflux has been observed in animal models3. •Clearance of from the blood is believed to be mainly via the liver, kidney and spleen4. •Data from human studies indicate that the about 6% of the Ab pool present in the cerebrospinal fluid is cleared per hour5. •There are no data available on the magnitude of the cerebral output of Ab peptides in man or the hepatic uptake. •The aim of this work was to investigate if the concentration Ab peptides is different in jugular venous plasma and arterial plasma and so estimate direct values for both brain-to-blood Ab efflux and hepatic clearance in man.